Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies
Fioravante Capone, Matteo Lucchini, Elisabetta Ferraro, Assunta Bianco, Mariagrazia Rossi, Alessandra Cicia, Antonio Cortese, Alessandro Cruciani, Valeria De Arcangelis, Laura De Giglio, Francesco Motolese, Biagio Sancetta, Massimiliano Mirabella, Vincenzo Di Lazzaro
Topics & Concepts
MedicineFingolimodOcrelizumabImmunogenicityMultiple sclerosisImmunologyNatalizumabVaccinationAlemtuzumabImmune systemInternal medicineAntibodyRituximabSARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research StudiesImmunotherapy and Immune Responses